» Articles » PMID: 9832645

Glomerular and Tubular Function in Renal Transplant Patients Treated with and Without Ciclosporin A

Overview
Journal Nephron
Publisher Karger
Specialty Nephrology
Date 1998 Dec 2
PMID 9832645
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The present study evaluated whether chronically administered low-dose (<5 mg/kg) ciclosporin A (CsA) affects renal haemodynamics and tubular function in renal transplant recipients (RTx) when studied at nadir CsA blood levels. The renal clearance of lithium was used as an index of proximal tubular outflow of sodium and water. Effective renal plasma flow, glomerular filtration rate, and renal clearance of lithium were studied in 67 stable non-diabetic RTx and 44 healthy controls. Forty-eight of the RTx were treated with CsA, prednisone, and azathioprine. Nineteen were treated exclusively with prednisone and azathioprine. In RTx with a good graft function (serum-creatinine <125 micromol/l), no specific CsA-induced renal haemodynamic and tubular dysfunctions were evident. In CsA-treated RTx with a slightly reduced renal function (serum creatinine 125-180 micromol/l) a decrease in fractional proximal tubular reabsorption was found. The renal clearances of urate and magnesium were comparable between RTx treated with or without CsA, and a significant correlation between glomerular filtration rate and renal clearance of urate was found. CsA-treated RTx had a significantly higher blood pressure, independent of glomerular filtration rate and segmental tubular function. In conclusion, at nadir CsA blood levels, no specific CsA-induced tubular dysfunction evaluated by the renal lithium clearance method could be demonstrated in RTx receiving chronically low-dose CsA. The hyperuricaemia commonly seen in RTx seems to be mainly caused by the reduced glomerular filtration rate.

Citing Articles

Gout: global epidemiology, risk factors, comorbidities and complications: a narrative review.

Motlagh Asghari K, Zahmatyar M, Seyedi F, Motamedi A, Zolfi M, Alamdary S BMC Musculoskelet Disord. 2024; 25(1):1047.

PMID: 39702222 PMC: 11660718. DOI: 10.1186/s12891-024-08180-9.


Bempedoic Acid, the First-in-Class Oral ATP Citrate Lyase Inhibitor with Hypocholesterolemic Activity: Clinical Pharmacology and Drug-Drug Interactions.

Ferri N, Colombo E, Corsini A Pharmaceutics. 2024; 16(11).

PMID: 39598495 PMC: 11597693. DOI: 10.3390/pharmaceutics16111371.


Hyperuricemia after orthotopic liver transplantation: divergent associations with progression of renal disease, incident end-stage renal disease, and mortality.

Longenecker J, Waheed S, Bandak G, Murakami C, McMahon B, Gelber A BMC Nephrol. 2017; 18(1):103.

PMID: 28347282 PMC: 5369182. DOI: 10.1186/s12882-017-0518-5.


Pathophysiology, clinical presentation and treatment of gout.

Teng G, Nair R, Saag K Drugs. 2006; 66(12):1547-63.

PMID: 16956303 DOI: 10.2165/00003495-200666120-00002.


Hyperuricemia and gout following pediatric renal transplantation.

Sparta G, Kemper M, Neuhaus T Pediatr Nephrol. 2006; 21(12):1884-8.

PMID: 16947031 DOI: 10.1007/s00467-006-0257-5.